Pharming And Orchard Seek Stem Cell Solution To Hereditary Angioedema
Duo To Develop Hematopoietic Stem Cell Gene Therapy
Orchard Therapeutics of the US and Dutch biotech Pharming have agreed to jointly research, develop, manufacture and commercialize the former’s newly disclosed investigational ex vivo autologous hematopoietic stem cell gene therapy as a treatment for hereditary angioedema.
You may also be interested in...
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.
Positive topline Phase II data for Ionis’ antisense hereditary angioedema candidate has boosted the biotech’s chances of developing PKK-LRx as a treatment for the disease.
The company sees KVD900 as potentially “ideal” for patients using on-demand and prophylactic therapy, given the existing need to carry backup on-demand medications.